Welcome to our dedicated page for Aehr Test Sys SEC filings (Ticker: AEHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aehr Test Systems (NASDAQ: AEHR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a California-based supplier of semiconductor test and burn-in systems, Aehr uses these filings to report on financial performance, corporate governance, equity compensation plans, and other material events.
Investors can review current reports on Form 8-K, where Aehr discloses items such as quarterly and annual financial results, amendments to equity incentive and employee stock purchase plans, and outcomes of shareholder votes at its annual meetings. For example, recent 8-K filings describe the approval of amendments to the 2023 Equity Incentive Plan and the Amended and Restated 2006 Employee Stock Purchase Plan, as well as the ratification of the company’s independent registered public accounting firm.
The company’s proxy statement on Schedule DEF 14A provides detail on director elections, executive compensation proposals, advisory votes on pay and pay frequency, and the matters submitted to shareholders at the annual meeting. These documents help investors understand Aehr’s board structure, compensation programs, and shareholder voting results.
On Stock Titan, Aehr’s filings are updated in near real time from EDGAR. Users can access 8-Ks for earnings announcements and other material events, proxy materials for governance and compensation information, and related exhibits referenced in those filings. AI-powered summaries highlight key points, allowing readers to quickly see how developments in Aehr’s semiconductor test and burn-in business—spanning FOX wafer-level systems and Sonoma, Echo, and Tahoe package-level platforms—are reflected in its official disclosures.
Aehr Test Systems director Geoffrey Scott reported a charitable stock transfer. On a Form 4, he disclosed a bona fide gift of 5,104 shares of common stock to the Scott Family Fund. After the donation, he directly owns 52,864 shares and indirectly holds 60,686 shares through a trust and 140,000 shares through his spouse, with some amounts including unvested restricted stock units.
AEHR Test Systems Executive VP of R&D Didier Wimmers reported a tax-related share withholding tied to restricted stock units. On March 3, 2026, 364 shares of common stock were withheld at $41.64 per share to cover tax obligations, not as an open-market sale. Following this, he held 14,186 shares, which the disclosure notes includes unvested restricted stock units.
AEHR TEST SYSTEMS CFO Chris Siu reported a tax-related share withholding transaction. On March 1, 2026, 368 shares of common stock were withheld at
Following this transaction, Siu directly owned 72,258 shares of common stock, and an additional 5,211 shares were held indirectly by a trust. The indirect position is reported as a holding entry, without a specified buy or sell action.
AEHR filed a notice under Rule 144 for a planned sale of 13,998 shares of its common stock. The shares are expected to be sold through Oppenheimer & Co. on the NASDAQ around 02/13/2026, with an aggregate market value listed as 390404.22.
The securities were originally acquired from the issuer on 10/18/2023 as compensation, in a single transaction for 13,998 shares. The filing notes that 30,627,342 shares of this class were outstanding, providing context for the size of the planned sale.
Aehr Test Systems director Rhea J. Posedel reported an insider sale of common stock through a trust associated with her. On February 13, 2026, the trust sold 13,998 shares of Aehr Test Systems common stock in an open-market transaction at $30.0151 per share.
After this transaction, the trust continued to hold 456,979 shares indirectly. Posedel also directly held 71,163 shares, and this direct amount includes shares subject to unvested restricted stock units.
Aehr Test Systems officer Alistair N. Sporck reported selling company stock. On 02/09/2026, Sporck, VP Contactor Business Unit, sold 2,700 shares of common stock at $27.57 per share and 300 shares at $27.59 per share, leaving 25,153 shares held directly and 5,214 shares held indirectly by a trust, which include shares subject to unvested restricted stock units.
A shareholder of AEHR has filed a Rule 144 notice to sell 3,000 shares of common stock, with an aggregate market value of $82,715.25. The planned sale is through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 02/09/2026.
The filing notes that 30,627,342 shares of common stock were outstanding. The 3,000 shares to be sold were acquired through multiple restricted stock vesting compensation events between 10/02/2025 and 01/27/2026, with each vesting treated as compensation from the issuer.
Baillie Gifford & Co has reported a passive stake in AEHR Test Systems’ common stock below the 5% threshold. The firm beneficially owns 1,290,734 shares, representing 4.3% of the class, with sole voting and dispositive power over all of these shares.
Baillie Gifford & Co, an investment adviser based in Scotland, states that the AEHR shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the company or participating in any control-related transactions.
Aehr Test Systems director Howard T. Slayen reported gifting 15,000 shares of common stock to family trusts. On 02/04/2026, he made three separate transfers of 5,000 shares each at a reported price of $0 per share, reflecting non-cash gifts.
The gifts went to the Leila James Slayen Trust, the Allison Elizabeth Slayen Trust, and the Max William Slayen Trust. After these transactions, Slayen beneficially owned 203,328 shares of Aehr Test Systems common stock, which the filing states includes shares subject to unvested restricted stock units.
AEHR Test Systems executive Alberto Salamone reported a small insider transaction related to equity compensation. On February 1, 2026, 234 shares of common stock were withheld at $25.64 per share to cover tax obligations when his restricted stock units vested. The filing explains this was not an open-market sale, but a share withholding for taxes. After this transaction, he beneficially owns 76,906 shares of AEHR common stock, which includes shares subject to unvested restricted stock units.